General Review| Volume 32, P145-175, April 2016

Do Medications Commonly Prescribed to Patients with Peripheral Arterial Disease Have an Effect on Nutritional Status? A Review of the Literature

Published:January 21, 2016DOI:


      Polypharmacy is common among patients with peripheral arterial disease (PAD) with a combination of medications used for risk-factor modification and medical management of the disease itself. Interaction between commonly prescribed medications and nutritional status has not previously been well described. This review aims to critically appraise evidence exploring associations between medications commonly prescribed to patients with PAD and nutritional status and provide recommendations for practice.


      A comprehensive literature search was conducted to locate studies relating to nutrient interactions among lipid-lowering, antihypertensive, antiplatelet, and oral hypoglycemic drug classes. Quality of the evidence was rated on the basis of recommendations by the National Health and Medical Research Council.


      A total of 25 articles were identified as suitable and included in the review. No studies were specific to patients with PAD, and hence findings highlighting risk of ubiquinone (coenzyme Q10 [CoQ10]) depletion with lipid-lowering medications, zinc depletion with antihypertensive medications, and vitamin B12 depletion with oral hypoglycemic medications are extrapolated from heterogeneous groups of patients and healthy adults. The body of evidence ranged in quality from satisfactory to poor.


      High-quality research is required to confirm the interactions suggested by the included studies in patients with PAD specifically. It is, however, recommended that patients with PAD that are long-term consumers of the selected medications are monitored for CoQ10, zinc, and vitamin B12 to facilitate early identification of deficiencies and initiation of treatment. Treatment may involve dietary intervention and/or supplementation.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Annals of Vascular Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Langlois M.
        • Duprez D.
        • Delanghe J.
        • et al.
        Serum vitamin C concentration is low in peripheral arterial disease and is associated with inflammation and severity of atherosclerosis.
        Circulation. 2001; 103: 1863-1868
      1. Lower Limb Peripheral Arterial Disease: Diagnosis & Management [Internet]. National Clinical Guideline Centre, 2012
        • Brook-Barclay L.
        • Delaney C.L.
        • Scicchitano M.
        • et al.
        Pharmacist influence on prescribing in peripheral arterial disease (PIPER).
        Vasc Med (London, England). 2014; 19: 118-124
        • Norgren L.
        • Hiatt W.R.
        • Dormandy J.A.
        • et al.
        Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II).
        Eur J Vasc Endovasc Surg. 2007; 33: S1-S75
        • Pande R.L.
        • Perlstein T.S.
        • Beckman J.A.
        • Creager M.A.
        Secondary prevention and mortality in peripheral artery disease: National Health and Nutrition Examination Study, 1999 to 2004.
        Circulation. 2011; 124: 17-23
        • Mason P.
        Important drug–nutrient interactions.
        Proc Nutr Soc. 2010; 69: 551-557
        • Samaras D.
        • Samaras N.
        • Lang P.O.
        • et al.
        Effects of widely used drugs on micronutrients: a story rarely told.
        Nutrition (Burbank, Los Angeles County, Calif). 2013; 29: 605-610
        • LaValle J.B.
        Hidden disruptions in metabolic syndrome: drug-induced nutrient depletion as a pathway to accelerated pathophysiology of metabolic syndrome.
        Altern Ther Health Med. 2006; 12 (quiz 2–3): 26-31
        • Stabler S.P.
        Vitamin B12 deficiency.
        N Engl J Med. 2013; 368: 149-160
      2. Public Health Resource Unit. The Critical Skills Appraisal Programme: making sense of evidence 2006. Available from:!who-is-casp-for/cz5t. Accessed December 10, 2014.

        • Bargossi A.M.
        • Grossi G.
        • Fiorella P.L.
        • et al.
        Exogenous CoQ10 supplementation prevents plasma ubiquinone reduction induced by HMG-CoA reductase inhibitors.
        Mol Aspects Med. 1994; 15: s187-s193
        • Berthold H.K.
        • Naini A.
        • Di Mauro S.
        • et al.
        Effect of ezetimibe and/or simvastatin on coenzyme Q10 levels in plasma: a randomised trial.
        Drug safety. 2006; 29: 703-712
        • Bleske B.E.
        • Willis R.A.
        • Anthony M.
        • et al.
        The effect of pravastatin and atorvastatin on coenzyme Q10.
        Am Heart J. 2001; 142: E2
        • De Pinieux G.
        • Chariot P.
        • Ammi-Said M.
        • et al.
        Lipid-lowering drugs and mitochondrial function: effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio.
        Br J Clin Pharmacol. 1996; 42: 333-337
        • Elmberger P.G.
        • Kalen A.
        • Lund E.
        • et al.
        Effects of pravastatin and cholestyramine on products of the mevalonate pathway in familial hypercholesterolemia.
        J Lipid Res. 1991; 32: 935-940
        • Ghirlanda G.
        • Oradei A.
        • Manto A.
        • et al.
        Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study.
        J Clin Pharmacol. 1993; 33: 226-229
        • Human J.A.
        • Ubbink J.B.
        • Jerling J.J.
        • et al.
        The effect of Simvastatin on the plasma antioxidant concentrations in patients with hypercholesterolaemia.
        Clin Chim Acta. 1997; 263: 67-77
        • Jula A.
        • Marniemi J.
        • Huupponen R.
        • et al.
        Effects of diet and simvastatin on serum lipids, insulin, and antioxidants in hypercholesterolemic men: a randomized controlled trial.
        JAMA. 2002; 287: 598-605
        • Laaksonen R.
        • Jokelainen K.
        • Laakso J.
        • et al.
        The effect of Simvastatin treatment on natural antioxidants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle.
        Am J Cardiol. 1996; 77: 851-854
        • Laaksonen R.
        • Jokelainen K.
        • Sahi T.
        • et al.
        Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans.
        Clin Pharmacol Ther. 1995; 57: 62-66
        • Mortensen S.A.
        • Leth A.
        • Agner E.
        • Rohde M.
        Dose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors.
        Mol Aspects Med. 1997; 18: S137-S144
        • Rundek T.
        • Naini A.
        • Sacco R.
        • et al.
        Atorvastatin decreases the coenzyme Q10 level in the blood of patients at risk for cardiovascular disease and stroke.
        Arch Neurol. 2004; 61: 889-892
        • Watts G.F.
        • Castelluccio C.
        • Rice-Evans C.
        • et al.
        Plasma coenzyme Q (ubiquinone) concentrations in patients treated with simvastatin.
        J Clin Pathol. 1993; 46: 1055-1057
        • Stolberg H.O.
        • Norman G.
        • Trop I.
        Randomized controlled trials.
        Am J Roentgenol. 2004; 183: 1539-1544
        • National Health and Medical Research Council
        NHMRC additional levels of evidence and grades for recommendations for developers of guidelines.
        NHMRC, Australia2009
        • Sarter B.
        Coenzyme Q10 and cardiovascular disease: a review.
        J Cardiovasc Nurs. 2002; 16: 9-20
        • Rasmussen C.B.
        • Glisson J.K.
        • Minor D.S.
        Dietary supplements and hypertension: potential benefits and precautions.
        J Clin Hypertens (Greenwich, Conn). 2012; 14: 467-471
        • Garrido-Maraver J.
        • Cordero M.D.
        • Oropesa-Avila M.
        • et al.
        Clinical applications of coenzyme Q10.
        Front Biosci (Landmark Ed). 2014; 19: 619-633
        • Spark J.I.
        • Chetter I.C.
        • Gallavin L.
        • et al.
        Reduced total antioxidant capacity predicts ischaemia-reperfusion injury after femorodistal bypass.
        Br J Surg. 1998; 85: 221-225
        • Sahud M.
        • Cohen R.
        Effect of aspirin ingestion on ascorbic-acid levels in rheumatoid arthritis.
        Lancet. 1971; 297: 937-938
        • Schulz H.U.
        • Schürer M.
        • Krupp S.
        • et al.
        Effects of acetylsalicylic acid on ascorbic acid concentrations in plasma, gastric mucosa, gastric juice and urine–a double-blind study in healthy subjects.
        Int J Clin Pharmacol Ther. 2004; 42: 481-487
        • Golik A.
        • Modai D.
        • Averbukh Z.
        • et al.
        Zinc metabolism in patients treated with captopril versus enalapril.
        Metabolism. 1990; 39: 665-667
        • Golik A.
        • Modai D.
        • Weissgarten J.
        • et al.
        Hydrochlorothiazide-amiloride causes excessive urinary zinc excretion.
        Clin Pharmacol Ther. 1987; 42: 42-44
        • Golik A.
        • Zaidenstein R.
        • Dishi V.
        • et al.
        Effects of captopril and enalapril on zinc metabolism in hypertensive patients.
        J Am Coll Nutr. 1998; 17: 75-78
        • Koren-Michowitz M.
        • Dishy V.
        • Zaidenstein R.
        • et al.
        The effect of losartan and losartan/hydrochlorothiazide fixed-combination on magnesium, zinc, and nitric oxide metabolism in hypertensive patients: a prospective open-label study*.
        Am J Hypertens. 2005; 18: 358-363
        • Tsuruoka S.
        • Wakaumi M.
        • Araki N.
        • et al.
        Comparative study of taste disturbance by losartan and perindopril in healthy volunteers.
        J Clin Pharmacol. 2005; 45: 1319-1323
        • Lansdown A.B.
        • Mirastschijski U.
        • Stubbs N.
        • et al.
        Zinc in wound healing: theoretical, experimental, and clinical aspects.
        Wound Rep Regen. 2007; 15: 2-16
        • Lowe N.M.
        • Fekete K.
        • Decsi T.
        Methods of assessment of zinc status in humans: a systematic review.
        The Am J Clin Nutr. 2009; 89: 2040S-2051S
        • Mocchegiani E.
        • Romeo J.
        • Malavolta M.
        • et al.
        Zinc: dietary intake and impact of supplementation on immune function in elderly.
        Age (Dordrecht, Netherlands). 2013; 35: 839-860
        • Ting R.Z.
        • Szeto C.C.
        • Chan M.H.
        • et al.
        Risk factors of vitamin B(12) deficiency in patients receiving metformin.
        Archives of internal medicine. 2006; 166: 1975-1979
        • de Jager J.
        • Kooy A.
        • Lehert P.
        • et al.
        Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial.
        BMJ. 2010; 340: c2181
        • Wulffele M.G.
        • Kooy A.
        • Lehert P.
        • et al.
        Effects of short-term treatment with metformin on serum concentrations of homocysteine, folate and vitamin B12 in type 2 diabetes mellitus: a randomized, placebo-controlled trial.
        J Int Med. 2003; 254: 455-463
      3. Australian Institute of Health and Welfare (AIHW). Diabetes risk factors 2013 [cited 2014 August 4]. Available from: Accessed December 10, 2014.

        • Gardner A.W.
        • Bright B.C.
        • Ort K.A.
        • Montgomery P.S.
        Dietary intake of participants with peripheral artery disease and claudication.
        Angiology. 2011; 62: 270-275
        • Delaney C.
        • Miller M.
        • Dickinson K.
        • Spark J.
        Change in dietary intake of adults with intermittent claudication undergoing a supervised exercise program and compared to matched controls.
        Nutr J. 2014; 13: 100